AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17578934
Drug: Daily positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily positive mood states
Trial: 9672274
Drug: Tamoxifen 20
RxNorm normalized name: tamoxifen 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 20 mg per day orally
Trial: 3063718
Drug: Methylphenidate 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.15 mg/kg
Trial: 3063718
Drug: Methylphenidate 0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.30 mg/kg
Trial: 3338232
Drug: Methylphenidate 0.50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.50 mg/kg
Trial: 20094015
Drug: 1-mg estradiol
RxNorm normalized name: estradiol 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-mg estradiol and 0.5-mg norethisterone (hormone therapy)
Trial: 15974555
Drug: Nurse-administered 6-month
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered 6-month telephonic case management intervention (Asthma Treatment Awareness Project)
Trial: 10503585
Drug: Lamotrigine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (25 mg for 2 weeks, 50 mg for 2 weeks, and 100 mg for 4 weeks)
Trial: 10503585
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets (taken once daily)
Trial: 8941876
Drug: Low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose IL-2 (1.2 x 10(6) IU/m2)
Trial: 8941876
Drug: High-dose IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IL-2 (1.2 x 10(7) IU/m2)
Trial: 2010875
Drug: CNS prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS prophylaxis treatment including cranial irradiation and intrathecal methotrexate
Trial: 2010875
Drug: CNS prophylaxis
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNS prophylaxis treatment including only intrathecal methotrexate and intermediate dose infusions of methotrexate
Trial: 7023527
Drug: Sustained-release aminophylline
RxNorm normalized name: aminophylline Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release aminophylline
Trial: 19957798
Drug: Low-dose Methotrexate
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Methotrexate + Leflunomide (MTX + LEF)
Trial: 17922442
Drug: Multifactorial therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifactorial therapeutic approach (glycemic control, antihypertensive therapy, RAAS inhibition, statins, aspirin)
Trial: 17922442
Drug: Optimal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal blood pressure levels < 130/80 mmHg for proteinuria < 1 g/day
Trial: 17922442
Drug: Optimal blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal blood pressure levels < 120/75 mmHg for proteinuria ≥ 1 g/day
Trial: 15781600
Drug: Psycho-educational program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psycho-educational program (10 weekly sessions)
Trial: 11981724
Drug: Amoxicillin/clavulanate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (90 mg/kg per day)
Trial: 9609359
Drug: alpha‐tocopherol nicotinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐tocopherol nicotinate 300 mg tds after meals for 3 months
Trial: 8553592
Drug: Spirapril monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril monotherapy
Trial: 2797894
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of cefamandole at induction of anaesthesia and 750 mg every six hours during 24 hours after surgery
Trial: 2797894
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of 1.5 g of cefamandole at induction of anaesthesia
Trial: 381229
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg ascorbic acid daily
Trial: 381229
Drug: 4000 mg
RxNorm normalized name: talc 4000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4000 mg ascorbic acid daily
Trial: 30069600
Drug: Dydrogesterone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone (20 mg/day) plus HMG (150 or 225 IU)
Trial: 24430001
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen
Trial: 27300114
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (after 48 months of treatment)
Trial: 25112084
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Baihui (GV 20), Sishencong (EX‐HN 1), Neiguan (PC 6), Zusanli (ST 36), and Hegu (LI 4) for 20 minutes, twice a week for 10 treatments.
Trial: 25112084
Drug: Delayed acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed acupuncture (no treatment during observation stage).
Trial: 22192643
Drug: Valsartan/Amlodipine 80/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine 80/5 mg (single dose)
Trial: 22192643
Drug: Valsartan/Amlodipine 80/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine 80/5 mg (multiple dose, once-daily for 9 days)
Trial: 22192643
Drug: Valsartan/Amlodipine 80/5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan/Amlodipine 80/5 mg (single and multiple doses)
Trial: 11793614
Drug: cilomilast 15
RxNorm normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilomilast 15 mg twice daily
Trial: 9745987
Drug: Melatonin (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (6 mg), administered 2 hr before habitual bedtime
Trial: 2467328
Drug: Low-fibre diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fibre diet during and after first cycle of cisplatin and vinblastine chemotherapy (Group 1)
Trial: 29722943
Drug: Testosterone Undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone Undecanoate Pills (TUP)
Trial: 29722943
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (maintaining glucose- and lipid-reducing therapies)
Trial: 26070917
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg orally once daily
Trial: 16957145
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant chemotherapy (Control)
Trial: 24910102
Drug: Ketamine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.4 mg/kg
Trial: 12859309
Drug: Lidocaine 2.5
RxNorm normalized name: LIDOCAINE 2.5% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2.5 mg/kg
Trial: 16159930
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH (n = 53)
Trial: 16159930
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (n = 31)
Trial: 1779084
Drug: Active based
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active based cream F14001
Trial: 1779084
Drug: Placebo non-active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo non-active based cream
Trial: 6122463
Drug: 160 mg
RxNorm normalized name: nadolol 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg oxprenolol
Trial: 6111331
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg sotalol
Trial: 31122797
Drug: Maternal triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal triple antiretroviral treatment throughout both ante‐partum and post‐partum phases
Trial: 31122797
Drug: Maternal non-adherence
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal non-adherence to triple antiretroviral treatment
Trial: 31122797
Drug: Maternal triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal triple antiretroviral treatment
Trial: 8070935
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B alone (0.5 mg/kg/day; n = 14)
Trial: 8070935
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.5 mg/kg/day) plus 5-flucytosine (150 mg/kg/day; n = 14)
Trial: 31561960
Drug: Atorvastatin (0.125-0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (0.125-0.75 mg/kg/day)
Trial: 31561960
Drug: Atorvastatin (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (0.75 mg/kg/day)
Trial: 23853246
Drug: Ixabepilone 40
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 40 mg/m2 (3‐hour infusion) every 3 weeks for four cycles
Trial: 23853246
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel 80 mg/m2 (1‐hour infusion) for 12 weeks
Trial: 18290863
Drug: Supportive psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive psychotherapy treatment
Trial: 16817265
Drug: Phased whole
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phased whole acupuncture therapy
Trial: 12923621
Drug: Enteral glutamine
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral glutamine (20 g/l)
Trial: 12923621
Drug: Control (isonitrogenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (isonitrogenous and isojoulic solution)
Trial: 8237969
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (3 g of calcium carbonate daily)
Trial: 3815460
Drug: Human leukocyte
RxNorm normalized name: Human leukocyte antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human leukocyte interferon (100 micrograms daily for nine weeks)
Trial: 21083771
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 40 puffs of 0.2 mg salbutamol
Trial: 21083771
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two placebo tablets)
Trial: 18797274
Drug: New anticholinergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New anticholinergic medications
Trial: 15983464
Drug: Sequential Epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Epidural Bolus (SEB) technique
Trial: 15983464
Drug: Continuous Epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Epidural Infusion (CEI) technique
Trial: 12209503
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg tacrolimus
Trial: 10645753
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg tacrolimus
Trial: 12209503
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tacrolimus
Trial: 7476742
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg oral tablet on admission, followed by 50 mg infusion in 250 ml dextrose 5% over 30 minutes)
Trial: 7476742
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg oral tablet and 100 mg infusion in 250 ml dextrose 5% over 30 minutes)
Trial: 1683545
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of activated charcoal administered simultaneously with 400 mg amiodarone
Trial: 1683545
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g of activated charcoal administered 1.5 hours after 400 mg amiodarone
Trial: 1683545
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 400 mg amiodarone and water only
Trial: 20382428
Drug: Topical nonsteroidal
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nonsteroidal anti-inflammatory drug (ketorolac)
Trial: 20382428
Drug: Topical steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroid (fluorometholone)
Trial: 14646439
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine gel (Instillagel) intraurethrally for approximately 15 min
Trial: 14646439
Drug: Water-soluble gel
RxNorm normalized name: WATER SOLUBLE BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-soluble gel (Aquagel) smeared around the scope and external urethral meatus
Trial: 15531005
Drug: Sibutramine 10
RxNorm normalized name: sibutramine 10 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine 10 mg once daily
Trial: 28134604
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no buccal grafting)
Trial: 24998121
Drug: Chronic warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic warfarin therapy
Trial: 19233692
Drug: Sequential deferiprone-deferoxamine
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sequential deferiprone-deferoxamine (DFP-DFO)
Trial: 17595355
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg q.d. for 12 weeks followed by 45 mg q.d. for another 12 weeks)
Trial: 17595355
Drug: Rosiglitazone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (4 mg q.d. followed by 4 mg b.i.d. for the same intervals)
Trial: 1423953
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units urokinase i.v. over 90 minutes plus intravenous heparin (group A)
Trial: 1423953
Drug: 3 million
RxNorm normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 million units urokinase i.v. plus 325 mg aspirin p.o. daily (group B)
Trial: 1423953
Drug: Placebo thrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo thrombolytic infusion plus full‐dose heparin (group C)
Trial: 27136622
Drug: Adalimumab 40
RxNorm normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 40 mg weekly (ew)
Trial: 20819563
Drug: G-CSF (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (10 microg/kg of body weight, daily) for continuous 7 days
Trial: 17178185
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (30 patients)
Trial: 12672860
Drug: Memantine 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 20 mg daily for 28 weeks
Trial: 8617705
Drug: Sertraline 100
RxNorm normalized name: sertraline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline 100 micrograms plus atenolol 50 mg
Trial: 8617705
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus atenolol 50 mg
Trial: 3888388
Drug: vindesine plus
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vindesine plus cisplatin (vindesine 3 mg/m2, cisplatin 120 mg/m2)
Trial: 3888388
Drug: vinblastine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinblastine plus cisplatin (vinblastine 6 mg/m2, cisplatin 120 mg/m2)
Trial: 30621836
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy with symptoms
Trial: 30249632
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of myo-inositol powder, twice daily until delivery
Trial: 30249632
Drug: Placebo, twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily until delivery
Trial: 27487640
Drug: Rectal acetaminophen
RxNorm normalized name: acetaminophen Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal acetaminophen
Trial: 18082485
Drug: 1 daily
RxNorm normalized name: PAXLOVID 150MGX2/100MGX1 DAILY PKT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 daily injection of insulin glargine (titrated to achieve fasting plasma glucose < or = 5.3 mmol/L)
Trial: 18082485
Drug: omega‐3‐acid ethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega‐3‐acid ethyl esters 90 (1 g consisting of EPA 465 mg and DHA 375 mg)
Trial: 11726736
Drug: Melatonin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (20 mg orally in two doses of 10 mg each, with a 1-h interval)
Trial: 9323286
Drug: Single-dose and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose and divided-dose prednisolone
Trial: 8517508
Drug: Background infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Background infusion (BI) at 1 mg/hr with patient-controlled analgesia (PCA)
Trial: 3705683
Drug: Diltiazem (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (3 X 60 mg daily)
Trial: 11199945
Drug: Fluoxetine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine plus pindolol
Trial: 24731672
Drug: Exenatide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (2 mg subcutaneous injection once weekly)
Trial: 24731672
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (titrated to target once daily)
Trial: 16006907
Drug: Cranberry juice
RxNorm normalized name: cranberry juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry juice (CBJ) 1 liter daily
Trial: 7016800
Drug: EMD 21
RxNorm normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMD 21 657 (3 X 400 mg/day p.o.) + maprotiline (75 mg/day p.o.)
Trial: 7016800
Drug: maprotiline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maprotiline (75 mg/day p.o.)
Trial: 12032024
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 90 mg
Trial: 6711779
Drug: Cimetidine 10
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 10 mg/kg orally given 120-180 minutes pre-operatively
Trial: 6711779
Drug: Cimetidine 10
RxNorm normalized name: cimetidine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 10 mg/kg orally
Trial: 27815799
Drug: Conjugated linoleic
RxNorm normalized name: CONJUGATED LINOLEIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conjugated linoleic acid (CLA) - 2 daily 1.25 g capsules (totaling about 2 g of CLA in glycerinated form)
Trial: 27815799
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 2 daily 1.25 g capsules containing sunflower oil with high oleic acid
Trial: 15756252
Drug: Capecitabine 1150
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1150 mg m‐2 twice daily with irinotecan 250 mg m‐2
Trial: 15756252
Drug: Capecitabine 1000
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg m‐2 with irinotecan 250 mg m‐2
Trial: 15756252
Drug: Capecitabine and
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine and irinotecan combination therapy
Trial: 12540205
Drug: Length-normalized pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Length-normalized pulse photoplethysmography (D/l)
Trial: 9681402
Drug: 0.4 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 g/kg HBOC‐201
Trial: 7988131
Drug: Sucralfate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (2 g every 8 hrs)
Trial: 7988131
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL of sterile water every 8 hrs)
Trial: 2521989
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (lower doses)
Trial: 4567765
Drug: Marijuana (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marijuana (dosage and smoking procedure standardized)
Trial: 4567765
Drug: Placebo (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (dosage and smoking procedure standardized)
Trial: 30169915
Drug: OIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OIT with pasteurized egg white (PEW), target dose 3.3 g PEW proteins, buildup pattern PI (30% weekly plus 5% daily increments)